Citigroup’s AnaptysBio ANAB Stock Holding History

Citigroup’s Portfolio ANAB Stock Details ANAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-21,700	Closed	-$403K	–	5642
2025 Q1	$403K	Sell	21,700 -5,000	-19%	-$83.4K	﹤0.01%	3791
2024 Q4	$354K	Buy	+26,700	New	+$647K	﹤0.01%	4054
2024 Q3	–	Sell	-24,000	Closed	-$601K	–	5666
2024 Q2	$601K	Sell	24,000 -6,000	-20%	-$140K	﹤0.01%	3270
2024 Q1	$676K	Hold	30,000	–	–	﹤0.01%	3341
2023 Q4	$643K	Hold	30,000	–	–	﹤0.01%	3213
2023 Q3	$539K	Hold	30,000	–	–	﹤0.01%	3000
2023 Q2	$610K	Buy	+30,000	New	+$608K	﹤0.01%	3230
2020 Q4	–	Sell	-1,200	Closed	-$18K	–	7343
2020 Q3	$18K	Sell	1,200 -500	-29%	-$9.02K	﹤0.01%	6259
2020 Q2	$38K	Sell	1,700 -2,200	-56%	-$40.2K	﹤0.01%	6186
2020 Q1	$55K	Sell	3,900 -2,500	-39%	-$37.9K	﹤0.01%	5889
2019 Q4	$104K	Buy	6,400 +4,800	+300%	+$114K	﹤0.01%	5741
2019 Q3	$56K	Sell	1,600 -1,600	-50%	-$76.1K	﹤0.01%	6051
2019 Q2	$181K	Buy	3,200 +3,000	+1,500%	+$216K	﹤0.01%	5349
2019 Q1	$15K	Sell	200 -1,600	-89%	-$110K	﹤0.01%	7081
2018 Q4	$115K	Sell	1,800 -6,500	-78%	-$483K	﹤0.01%	5531
2018 Q3	$828K	Buy	+8,300	New	+$689K	﹤0.01%	3706

Other funds holding ANAB

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Citigroup's ANAB Position: Q2 2026 in Review

Citigroup increased its AnaptysBio (ANAB) stake by 35% in Q2 2026, buying an estimated $1.56M and bringing the position to 99,114 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #1899.

Citigroup first reported a position in ANAB in Q1 2017 and has held it in 38 quarters since. The position peaked at $23.2M in Q2 2025. 213 funds tracked by Wall St. Rank hold ANAB as of Q2 2026.

Citigroup held 99,114 shares of AnaptysBio worth $6.69M as of Q2 2026.
Citigroup bought 25,708 AnaptysBio shares in Q2 2026, an estimated $1.56M.
AnaptysBio made up ﹤0.01% of Citigroup's portfolio in Q2 2026, its #1899 holding.
Citigroup first reported a position in AnaptysBio in Q1 2017 and has held it in 38 quarters since.
Citigroup's AnaptysBio position peaked at $23.2M in Q2 2025.
213 funds tracked by Wall St. Rank held AnaptysBio as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.